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Abstract
Background: There is limited information on the longer-term outcome after transcatheter aortic valve replacement
(TAVR) with new-generation prostheses compared to surgical aortic valve replacement (SAVR). The aim of this study
was to compare the mid-term outcomes after TAVR with Sapien 3 and SAVR with Perimount Magna Ease
bioprostheses for severe aortic stenosis.
Methods: In a retrospective study, we included patients who underwent transfemoral TAVR with Sapien 3 or SAVR
with Perimount Magna Ease bioprosthesis between January 2008 and October 2017 from the nationwide FinnValve
registry. Propensity score matching was performed to adjust for differences in the baseline characteristics. The
Kaplan-Meir method was used to estimate late mortality.
Results: A total of 2000 patients were included (689 in the TAVR cohort and 1311 in the SAVR cohort). Propensity
score matching resulted in 308 pairs (STS score, TAVR 3.5 ± 2.2% vs. SAVR 3.5 ± 2.8%, p = 0.918). In-hospital mortality
was 3.6% after SAVR and 1.3% after TAVR (p = 0.092). Stroke, acute kidney injury, bleeding and atrial fibrillation were
significantly more frequent after SAVR, but higher rate of vascular complications was observed after TAVR. The
cumulative incidence of permanent pacemaker implantation at 4 years was 13.9% in the TAVR group and 6.9% in
the SAVR group (p = 0.0004). At 4-years, all-cause mortality was 20.6% for SAVR and 25.9% for TAVR (p = 0.910). Four-
year rates of coronary revascularization, prosthetic valve endocarditis and repeat aortic valve intervention were
similar between matched cohorts.
Conclusions: The Sapien 3 bioprosthesis achieves comparable midterm outcomes to a surgical bioprosthesis with
proven durability such as the Perimount Magna Ease. However, the Sapien 3 bioprosthesis was associated with
better early outcome.
Trial registration: ClinicalTrials.gov Identifier: NCT03385915.
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Background
Transcatheter aortic valve replacement (TAVR) with
balloon-expandable [1–3] and self-expanding [4–7]
bioprosthesis has proven its efficacy and safety com-
pared to surgical aortic valve replacement (SAVR) in
the treatment of aortic stenosis (AS) regardless of the
operative risk. A meta-analysis of randomized con-
trolled trials recently showed that TAVR is associated
with significant reduction of all-cause mortality, a
lower risk for stroke, atrial fibrillation and bleeding,
but a higher risk for permanent pacemaker implant-
ation and major vascular complications at 2 years
compared to SAVR [8]. The indications for TAVR are
expanding, but it is controversial whether TAVR
should be performed on a larger scale because of lim-
ited data on the long-term outcome and valve dur-
ability of TAVR prostheses compared to SAVR
prostheses. Similar longer-term survival after TAVR
and SAVR is observed in randomized controlled trials
[1, 6, 7], but studies reporting outcomes in the real-
world populations have discordant findings [9–12].
Sustained valve hemodynamics and low reintervention
rate is associated with the use of first-generation
balloon-expandable Sapien bioprosthesis [1, 13]. How-
ever, a higher rate of structural valve deterioration
leading to hemodynamic compromise was observed
with the second-generation Sapien XT valve com-
pared to the third-generation Sapien 3 valve pros-
thesis and the surgical valves in the PARTNER 2 trial
[14]. Importantly, TAVR with different valve types
and their iterations may result in discrepant outcomes
and valve performance [14–16]. Therefore it is im-
portant to compare the outcomes of each TAVR
prosthesis separately against SAVR prostheses with
proven long-term durability [17, 18].
The third-generation balloon-expandable Sapien 3
(Edwards Lifesciences, Irvine, CA, USA) prosthesis has
bovine pericardial leaflets that are attached inside a
cobalt-chromium alloy frame, and unlike its predeces-
sors (Sapien, Sapien XT, Edwards Lifesciences, Irvine,
CA, USA) has an improved external layer of polyethyl-
ene terephthalate fabric seal to minimize the risk of
paravalvular regurgitation along with a redesigned frame.
During manufacturing, bovine pericardial leaflets
undergo the same tissue processing (ThermaFix)
intended to reduce the risk of leaflet calcification as in
the latest generation surgical Perimount Magna Ease
(Edwards Lifesciences, Irvine, CA, USA), which is
regarded as the most durable surgical bioprosthesis [17].
The aim of this study was to compare the outcome
after TAVR with the Sapien 3 and SAVR with the Peri-
mount Magna Ease bovine pericardial prostheses. To
our knowledge, this is the first direct comparison of
these TAVR and SAVR bioprostheses.
Methods
Registry design
The FinnValve registry collected data on consecutive pa-
tients who underwent TAVR or SAVR with a bioprosth-
esis for AS at all Finnish university hospitals (Helsinki,
Kuopio, Oulu, Tampere, Turku) between January 2008
and October 2017. Inclusion criteria were age > 18 years,
primary aortic valve procedure with a bioprosthesis
(TAVR or SAVR) for AS with or without associated cor-
onary revascularization. The exclusion criteria were any
prior aortic valve procedure, concomitant intervention
for other valve or ascending aorta, active endocarditis
and a procedure for aortic valve regurgitation. The study
protocol was approved by the local Institutional Review
Boards in all participating centres. Data was retrospect-
ively collected in a dedicated electronic case report sys-
tem by physicians and trained research nurses. Data on
mortality was obtained from the Finnish Population
Register Centre and data on cardiovascular interventions
was retrieved from the registry of the Finnish National
Institute for Health and Welfare. The follow-up was
complete, except for those few patients not residing in
Finland follow-up was truncated at hospital discharge.
The study followed the Strengthening the Reporting of
Observational Studies in Epidemiology guidelines [19].
Patients and outcomes
Only patients who underwent transfemoral TAVR
with Sapien 3 or SAVR with Perimount Magna Ease
were included in this analysis. The choice between
TAVR and SAVR was based on individual assessment
by the local Heart Team. Patients in the TAVR group
and concomitant coronary artery disease (CAD)
underwent revascularization based on the discretion
of the treating physician. Patients who underwent an
emergency procedure or with associated severe clin-
ical conditions were excluded (Fig. 1). The primary
outcomes were in-hospital and 4-year all-cause mor-
tality. The secondary outcomes were stroke, atrial fib-
rillation, permanent pacemaker implantation, major
vascular complications, acute kidney injury, dialysis,
moderate or severe paravalvular regurgitation, severe
bleeding, reoperation for bleeding, red blood cell
transfusion, annular or aortic rupture/dissection, con-
version to cardiac surgery, coronary artery occlusion,
deep sternal wound infection, postoperative intra-
aortic balloon pump or extracorporeal membrane
oxygenation, ventricular wall injury and length of
index hospitalization. Late secondary outcomes were
permanent pacemaker implantation, coronary revascu-
larization, prosthetic valve endocarditis and reopera-
tion on the implanted aortic bioprosthesis.
The European System for Cardiac Operative Risk
Evaluation (EuroSCORE) II criteria were applied for
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the definition of baseline variables and for surgical
risk stratification [20]. Surgical risk was estimated also
according to the Society of Thoracic Surgeons Pre-
dicted Risk of Mortality (STS-PROM) score. Coronary
artery disease was defined as a ≥ 50% stenosis in a
main coronary artery. Severe frailty was defined as
Geriatric Status Scale 2–3 [21]. Stroke and major vas-
cular complications were defined according to Valvu-
lar Academic Consortium 2 (VARC-2) [22] criteria
and severe bleeding according to European Coronary
Artery Bypass Grafting (E-CABG) bleeding scores 2–3
[23], i.e. transfusion of more than 4 units of red blood
cells and/or reoperation for bleeding. Acute kidney
injury was defined according to the KDIGO definition
criteria [24].
Statistical analysis
Statistical analyses were performed using SAS v. 9.2
(SAS Institute Inc., Cary, NC) and SPSS v. 25.0 (IBM
Corporation, New York, USA) statistical softwares. Data
is presented as means ± standard deviation for continu-
ous variables, and as counts and percentages for categor-
ical variables. Mann-Whitney’s test was used to compare
continuous variables, and the chi -square and Fisher’s
exact tests were used to compare the categorical vari-
ables in the unmatched cohorts. A propensity score was
calculated with a non-parsimonious logistic regression
model including the following variables: age, gender,
body mass index, diabetes, atrial fibrillation, extracardiac
arteriopathy, chronic lung disease, hemoglobin, esti-
mated glomerular filtration rate, stroke, pre-existing
Fig. 1 Study flow-chart
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pacemaker, previous cardiac surgery, previous percutan-
eous coronary intervention, coronary artery disease,
number of diseased coronaries, recent myocardial infarc-
tion, New York Heart Association class IV symptoms,
acute heart failure or critical preoperative state, urgent
procedure, left ventricular ejection fraction, systolic pul-
monary pressure, mitral valve regurgitation, frailty and
inactive malignancy. One-to-one propensity score
matching was performed using the nearest-neighbour
method and a caliper width of 0.2 of the standard devi-
ation of the logit of the propensity score. Baseline vari-
ables and in-hospital outcomes in the matched
population were compared with paired t-test and the
McNemar test. Kaplan-Meier method with Klein-
Moeschberger log-rank test was used to estimate late
mortality. The risk for late adverse events was calculated
with competing risk analysis and comparisons were per-
formed using the Gray’s k-sample test for equality of cu-
mulative incidence functions. Hazard ratios were
calculated with their 95% confidence intervals (CI). P <
0.05 was considered statistically significant.
Results
Study population
A total of 6463 patients were included in the FinnValve
registry, and after exclusion of 4463 patients (Fig. 1),
2000 patients were subjects for the present analysis.
Among them, 689 underwent TAVR with Sapien 3 bio-
prosthesis and 1311 patients underwent SAVR with Peri-
mount Magna Ease prosthesis. The mean follow-up of
the overall series and of the TAVR and SAVR cohorts
was 3.6 ± 2.1, 2.4 ± 1.0 and 4.2 ± 2.1 years, respectively.
The patients in the TAVR cohort were older (81.3 ± 6.4
vs. 74.0 ± 6.9 years), had more often co-morbidities and
higher surgical risk based on the EuroSCORE II and
STS-PROM scores (Table 1). After propensity score
matching, 308 pairs with balanced baseline variables
were identified (Table 1). The standardized difference
after matching was < 0.1 for all baseline and operative
covariates except for concomitant coronary revasculari-
zation, which was more common in SAVR (27.3% vs.
4.5%) despite a similar prevalence of coronary artery dis-
ease in the cohorts. The mean STS-PROM score was
3.5 ± 2.2% in the TAVR and 3.5 ± 2.8 in the SAVR co-
hort (p = 0.918) (Table 1). The sizes of implanted pros-
theses are summarized in Table 2.
Early outcomes
The early outcomes of the unmatched TAVR and SAVR
cohorts are summarized in Table 3.
In the propensity matched cohorts, TAVR had a nu-
merically lower in-hospital mortality (1.2% vs. 3.6%, p =
0.092) compared to SAVR (Table 3). Moreover, postop-
erative stroke was significantly less frequent after TAVR
(0.3% vs. 3.6%, p = 0.006). A trend towards a higher need
of permanent pacemaker implantation early after the
procedure was observed in the Sapien 3 group. The inci-
dence of moderate or severe paravalvular regurgitation
was similar in both cohorts. TAVR was associated with
lower rates of postoperative atrial fibrillation, acute kid-
ney injury and severe bleeding compared to SAVR
(Table 3). Major vascular complications were signifi-
cantly more frequent in the TAVR cohort. Annular rup-
ture occurred in one patient after Sapien 3 implantation
(Table 3).
Mid-term outcomes after procedures
In the matched cohorts, Kaplan-Meier estimate of all-
cause mortality was 7.5 and 6.5% at 1-year, 11.3 and
11.7% at 2-years, 12.9 and 14.7% at 3-years, 20.6 and
25.9% at 4-years in the SAVR and TAVR cohorts, re-
spectively (HR 0.96; 95% CI 0.63–1.46; p = 0.910) (Fig. 2).
At 4-years, the cumulative incidence of permanent pace-
maker implantation was higher after TAVR (13.9% vs.
6.9%; HR 2.16; 95% CI 1.27–3.68). TAVR was associated
with similar rates of late coronary revascularization
(1.5% vs. 1.4%; HR 0.76; 95% CI 0.17–3.43), prosthetic
valve endocarditis (0.6% vs. 0.5%; HR 1.02; 95% CI 0.06–
16.10) and repeat aortic valve intervention (0.4% vs.
0.4%; HR 1.02; 95% CI 0.06–16.14) compared to SAVR.
In the matched groups, one patient in the TAVR
group underwent aortic valve reintervention for struc-
tural valve deterioration and one patient in the SAVR
group for paravalvular regurgitation. Additionally, the
indications for reoperation in the unmatched cohorts
were structural valve deterioration (1 patient with Sapien
3, 1 patient with Perimount), paravalvular regurgitation
(5 patients with Perimount), and endocarditis (1 patient
with Perimount).
Discussion
The main findings of our study are the following: 1) pa-
tients treated for severe AS with the transfemoral TAVR
with the Sapien 3 bioprosthesis had similar mid-term
mortality compared to patients who underwent SAVR
with the Perimount Magna Ease bioprosthesis; 2) the
risk for coronary revascularization, repeat aortic valve
intervention and prosthetic valve endocarditis at 4 years
was low and similar with both bioprostheses; 3) the Sa-
pien 3 was associated with a higher cumulative rate of
permanent pacemaker implantation than the Perimount
Magna Ease bioprosthesis; 4) procedural safety in terms
of stroke, atrial fibrillation, kidney injury and bleeding
favoured TAVR, whilst lower rate of major vascular
complications was observed with SAVR.
We hypothesised that unbiased evaluation on the out-
comes after TAVR and SAVR could be feasible by in-
cluding only the Sapien 3 and the Perimount Magna
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Table 1 Baseline characteristics of the unmatched and propensity score matched cohorts
Unmatched cohort Propensity score matched cohort
Clinical variables Sapien 3
(N =
689)
Perimount Magna
Ease
(N = 1311)
Standardized
difference
p-
value
Sapien 3
(N =
308)
Perimount Magna
Ease
(N = 308)
Standardized
difference
p-
value
Age, yrs 81.3 ±
6.4
74.0 ± 6.9 1.1 <
0.0001
78.8 ±
6.9
79.0 ± 5.3 −0.03 0.697
Female 365
(53.0)
556 (42.4) 0.21 <
0.0001
160
(51.9)
165 (53.6) −0.03 0.674
BMI, kg/m2 27.4 ±
4.9
28.0 ± 4.8 −0.12 0.012 28.1 ±
5.2
28.0 ± 5.0 0.02 0.848
Diabetes mellitus 207
(30.0)
353 (26.9) 0.07 0.140 93 (30.2) 87 (28.2) 0.04 0.578
Atrial fibrillation 293
(42.5)
255 (19.5) 0.52 <
0.0001
102
(33.1)
99 (32.1) 0.02 0.782
Extracardiac arteriopathy 117
(17.0)
137 (10.5) 0.19 <
0.0001
49 (15.9) 41 (13.3) 0.07 0.383
Chronic lung disease 149
(21.6)
172 (13.1) 0.23 <
0.0001
65 (21.1) 62 (20.1) 0.02 0.761
Hemoglobin, g/l 125.7 ±
15.2
133.6 ± 15.1 −0.53 <
0.0001
128.7 ±
15.2
127.8 ± 15.3 0.06 0.421
eGFR, ml/m2/min 62.0 ±
18.5
72.6 ± 16.7 −0.60 <
0.0001
65.6 ±
18.1
66.4 ± 16.1 −0.05 0.550
History of stroke 70 (10.2) 70 (5.3) 0.18 0.0001 27 (8.8) 29 (9.4) −0.02 0.782
Prior pacemaker 65 (9.4) 50 (3.8) 0.23 <
0.0001
20 (6.5) 19 (6.2) 0.01 0.862
Previous cardiac surgery 110
(16.0)
24 (1.8) 0.51 <
0.0001
17 (5.5) 18 (5.8) −0.01 0.847
Prior PCI 140
(20.3)
130 (9.9) 0.29 <
0.0001
47 (15.3) 40 (13.0) 0.07 0.370
Coronary artery disease 181
(26.3)
563 (42.9) −0.36 <
0.0001
102
(33.1)
97 (31.5) 0.04 0.665
No. of diseased vessels 0.36 ±
0.7
0.78 ± 1.1 −0.48 <
0.0001
0.47 ±
0.8
0.46 ± 0.8 0.02 0.836
Recent MI 17 (2.5) 72 (5.5) −0.16 0.0018 9 (2.9) 9 (2.9) 0.00 1.000
NYHA class IV 82 (11.9) 94 (7.2) 0.16 0.0004 31 (10.1) 34 (11.0) −0.03 0.696
AHF 75 (10.9) 101 (7.7) 0.11 0.017 33 (10.7) 33 (10.7) 0.00 1.000
Urgent procedure 55 (8.0) 148 (11.3) −0.11 0.020 28 (9.1) 33 (10.7) −0.05 0.508
Ejection fraction 0.26 <
0.0001
0.08 0.699
> 50% 499
(72.4)
1069 (81.5) 230
(74.7)
239 (77.6)
31–50% 158
(22.9)
220 (16.8) 68 (22.1) 60 (19.5)
21–30% 31 (4.5) 22 (1.7) 10 (3.2) 9 (2.9)
Sys. pulmonary pressure 0.74 <
0.0001
0.09 <
0.0001
31–55mmHg 245
(35.6)
524 (40.0) 131
(42.5)
121 (39.3)
> 55 mmHg 75 (10.9) 92 (7.0) 34 (11.0) 39 (12.7)
Mitral valve regurgitation 0.56 <
0.0001
0.06 0.652
Mild 255
(37.0)
278 (21.2) 116
(37.7)
107 (34.7)
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Ease bioprostheses, because the bioprostheses share
some technological features such as bovine pericardial
leaflets utilizing similar anti-calcification processes dur-
ing manufacturing. Furthermore, the Perimount Magna
Ease demonstrated an excellent durability among
current surgical bioprostheses [17].
Our study showed that TAVR with the Sapien 3 pros-
thesis resulted in similar survival compared to SAVR
with the Perimount Magna Ease at 4-years. Comparable
mid-term outcomes between TAVR and SAVR were
achieved in randomized controlled trials [1, 6, 7], but
strict selection of the patients does not allow
generalization of the results into real-life AS patients
undergoing invasive treatment. Indeed, several observa-
tional studies have shown inferior mid-term outcomes
after TAVR compared to SAVR. The findings from the
OBSERVANT registry of 1300 matched patients under-
going TAVR with first/second generation prostheses and
SAVR showed that TAVR was associated with higher
all-cause mortality (44.5% vs. 35.8%) at 5-years. Mortality
rate in the OBSERVANT registry exceeded our 4-year
mortality already after 2.5 years [11]. Markedly inferior
5-year survival after TAVR was observed also in the ana-
lysis from the French Medical Information System data-
base, with all-cause death of 52% after TAVR and 37%
after SAVR in the matched patient populations [9].
There are few possible explanations for such different
mid-term outcomes between the studies. Firstly, the Sa-
pien 3 bioprosthesis carried a decreased risk of structural
valve deterioration compared to its predecessor the Sa-
pien XT valve, and performed similarly as the surgical
valves in the PARTNER 2 study [14]. In addition, a pro-
pensity score matched study combining data from the
SOURCE XT and the SOURCE 3 registries showed im-
proved survival with Sapien 3 compared to Sapien XT
valves [15]. A low incidence (1.9%) of moderate para-
valvular regurgitation with Sapien 3 in our study was in
concordance with other studies, and potentially im-
pacted the outcomes [25]. Secondly, including different
generations of balloon-expandable and self-expanding
TAVR prostheses in previous observational studies may
have introduced a significant bias [16].
The question of valve durability is becoming more
relevant as TAVR is adopted for lower- risk patients.
Several studies showed reasonable durability of surgical
bioprosthesis up to 15–20 years after SAVR [17], but
variable definitions used for structural valve deterior-
ation in surgical prostheses makes benchmarking for
transcatheter valves difficult [26]. The incidence of
structural valve deterioration cannot be estimated in our
study since a comprehensive echocardiographic follow-
up data was not available and solely reintervention rate
inevitably leads to a major underestimation of its true
incidence. This clearly limits the interpretation of our
results regarding the durability of the Sapien 3 pros-
thesis. However, the need for reintervention for aortic
valve complications was very low in both cohorts.
The cumulative incidence of permanent pacemaker
implantation in the Perimount group remained low and
stable, while in the Sapien 3 group permanent pace-
maker implantation was increasingly needed along the
study period. Since pacing after TAVR may have long-
term consequences for the patient [27], we should aim
to reduce the risk for permanent pacemaker
Table 1 Baseline characteristics of the unmatched and propensity score matched cohorts (Continued)
Unmatched cohort Propensity score matched cohort
Clinical variables Sapien 3
(N =
689)
Perimount Magna
Ease
(N = 1311)
Standardized
difference
p-
value
Sapien 3
(N =
308)
Perimount Magna
Ease
(N = 308)
Standardized
difference
p-
value
Moderate 80 (11.6) 39 (3.0) 23 (7.5) 21 (6.8)
Concomitant coronary
revascularization
29 (4.2) 511 (39.0) −0.78 <
0.0001
14 (4.5) 84 (27.3) −0.62 <
0.0001
EuroSCORE II, % 6.5 ± 7.1 3.4 ± 4.2 0.52 <
0.0001
5.0 ± 5.2 4.9 ± 5.9 0.02 0.752
STS-PROM, % 4.3 ± 2.9 2.6 ± 2.1 0.67 <
0.0001
3.5 ± 2.2 3.5 ± 2.8 0.01 0.918
Categorical values are reported as counts and percentages. Continuous variables are reported as mean and standard deviation. AHF acute heart failure (within 60
days before procedure or critical preoperative state), BMI body mass index, eGFR estimated glomerular filtration rate, EuroSCORE European System for Cardiac
Operative Risk Evaluation, MI myocardial infarction within 90 days before procedure, NYHA New York Heart Association, PCI percutaneous coronary intervention,
STS-PROM Society of Thoracic Surgeons Predicted Risk of Mortality
Table 2 Prosthesis sizes in the unmatched cohorts
Size Sapien 3
(N = 689)
Size Perimount Magna Ease
(N = 1311)
20 mm 2 (0.3) 19 mm 35 (2.7)
23 mm 221 (32.1) 21 mm 320 (24.4)
26 mm 256 (37.2) 23 mm 551 (42.0)
29 mm 206 (29.9) 25 mm 296 (22.6)
27 mm 95 (7.2)
29 mm 10 (0.8)
Categorical values are reported as counts and percentages
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implantation by adopting higher implantation technique
and avoiding excess oversizing with the Sapien 3 pros-
thesis [28, 29].
The prevalence of coronary artery disease was similar
in the matched cohorts, but concomitant coronary re-
vascularization was performed only in 14% of the
patients with coronary artery disease in the TAVR group
compared to 87% revascularization rate in patients with
coronary artery disease in the SAVR group. Complete
revascularization during SAVR is recommended to avoid
postoperative left ventricular systolic dysfunction and
excess mortality after surgery [30], but the best
Table 3 Outcomes in the unmatched and propensity score matched cohorts
Unmatched cohort Propensity score matched cohort
Outcomes Sapien 3
(N = 689)
Perimount Magna Ease
(N = 1311)
p-value Sapien 3
(N = 308)
Perimount Magna Ease
(N = 308)
p-value
In-hospital death 8 (1.2) 26 (2.0) 0.177 4 (1.3) 11 (3.6) 0.092
Stroke 9 (1.3) 48 (3.7) 0.003 1 (0.3) 11 (3.6) 0.006
Vascular complications < 0.0001 < 0.0001
Minor 18 (2.6) 0 8 (2.6) 0
Major 58 (8.4) 13 (1.0) 29 (9.4) 2 (0.6)
Annulus rupture 2 (0.3) 0 1 (0.3) 0
Aortic dissection/rupture 2 (0.3) 7 (0.5) 0.727 1 (0.3) 1 (0.3) 1.000
Coronary ostium occlusion 2 (0.3) 2 (0.2) 0.612 1 (0.3) 2 (0.6) 1.000
Acute kidney injury stages 2–3 5 (0.7) 72 (5.5) < 0.0001 1 (0.3) 24 (7.8) < 0.0001
Postoperative dialysis 2 (0.3) 20 (1.5) 0.012 0 7 (2.3) 0.015
Moderate/severe paravalvular regurgitation 8 (1.2) 10 (0.8) 0.370 6 (1.9) 4 (1.3) 0.754
Severe bleeding* 14 (2.1) 282 (21.9) < 0.0001 4 (1.3) 88 (29.0) < 0.0001
Reoperation for bleeding 14 (2.0) 129 (9.8) < 0.0001 7 (2.3) 33 (10.7) < 0.0001
Red blood cell transfusion, units 0.3 (1.1) 2.6 (3.4) < 0.0001 0.27 (1.0) 3.2 (3.5) < 0.0001
Postoperative IABP or ECMO 0 11 (0.8) 0.020 0 3 (1.0) 0.249
Atrial fibrillation 269 (39.0) 733 (55.9) < 0.0001 102 (33.1) 200 (64.9) < 0.0001
Permanent pacemaker implantation 52 (7.5) 47 (3.6) < 0.0001 28 (9.1) 16 (5.2) 0.064
Hospital stay, days 4.0 ± 3.4 7.7 ± 5.5 < 0.0001 4.1 ± 3.7 8.4 ± 6.8 < 0.0001
Categorical values are reported as counts and percentages. Continuous variables are reported as mean and standard deviation. ECMO extracorporeal membrane
oxygenation, IABP intra-aortic balloon pump; * = transfusion of more than 4 units of red blood cells and/or reoperation for bleeding
Fig. 2 Kaplan-Meier estimate of all-cause mortality after aortic valve replacement with Sapien 3 and Perimount Magna Ease bioprostheses in the
propensity score matched cohorts. P-value is from the Klein-Moeschberger log-rank test
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revascularization strategy during TAVR is not estab-
lished yet, which most likely explains the lower revascu-
larization rate in the TAVR group. Interestingly, such a
low rate of coronary revascularization at the time of pro-
cedure did not expose patients undergoing TAVR to an
increased need of revascularization at 4-years with simi-
lar mortality rate compared to SAVR. However, we have
to interpret this finding with caution because the in-
creased risk related to coronary artery disease in the
TAVR patients is driven by its severity [31], and our def-
inition criteria did not capture patients only with the
most severe coronary artery disease.
Procedural safety is one of the major concerns in the
decision-making process. The present findings indicate
that TAVR with balloon-expandable Sapien 3 is safe
with very low rates of annular rupture and coronary ob-
struction. Furthermore, TAVR was associated with lower
incidence of stroke, acute kidney injury, atrial fibrillation
and bleeding compared to SAVR. However, the rate of
major vascular complications was still higher in TAVR
compared to SAVR. This favourable safety profile of
TAVR over SAVR is in alignment with current know-
ledge [8].
Limitations
The retrospective nature is the major limitation of this
study. Secondly, the mean follow-up in the TAVR cohort
was shorter than in the SAVR cohort. Third, compara-
tive analysis of the TAVR and SAVR cohorts was based
on propensity score matching and unrecognized con-
founders might have had an impact on the results. Fi-
nally, the lack of complete echocardiographic follow-up
prevented an analysis of structural valve deterioration
which might have occurred in these cohorts.
Conclusions
In this nationwide study, transfemoral TAVR with Sa-
pien 3 prosthesis achieved similar mid-term outcomes
with better procedural safety compared to SAVR with
Perimount Magna Ease bioprosthesis.
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